for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ビジネス

Breakingviews TV: Gilead growth

The biotech giant is spending $5.1 billion on Belgian outfit Galapagos but won’t take control. That, says Robert Cyran, means Gilead can profit from the smaller drugmaker’s successes, while limiting the risk. It’s a smart move, as both Roche and Sanofi discovered.

最新のビデオ
世界のこぼれ話
スポーツ

ビジネス

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up